Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.
Signal Transduct Target Ther · 2026-Apr-13 · PMID 41968137
Overall survival
Fig. 4 Final analyses of OS. The HR and 95% CI for the difference between treatment groups in OS were estimated using the stratified Cox regression model, including treatment as the explanatory variable. a Kaplan‒Meier estimates of OS unadjusted for patients who received subsequent antitumor therapy. The differences in OS in this final analysis were not statistically significant on the basis of the allocated two-sided alpha level of 0.05. b , c Kaplan‒Meier estimates of OS adjusted for patients who received subsequent antitumor therapy, applying the naïve censoring method and the IPCW method ( b ) and the RPSFTM method ( c ). Patients at risk are not included in the IPCW model due to the lack of a clear clinical interpretation of the number of patients at risk associated with the weighted methodology. Analysis was performed on the intention-to-treat population. OS overall survival, IPCW inverse probability of censoring weighting, RPSFTM rank preserving structural failure time models
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | failed | 待验证 | 0 | 2026-07-23T16:48:20+00:00 |